Background: The antifibrotic effects of recombinant human relaxin (RLX) in the kidney are dependent on an interaction between its cognate receptor (RXFP1) and the angiotensin type 2 receptor (AT2R) in male models of disease. Whether RLX has therapeutic effects, which are also mediated via AT2R, in hypertensive adult and aged/reproductively senescent females is unknown. Thus, we determined whether treatment with RLX provides cardiorenal protection via an AT2R-dependent mechanism in adult and aged female stroke-prone spontaneously hypertensive rats (SHRSPs). Methods: In 6-month-old (6MO) and 15-month-old ([15MO]; reproductively senescent) female SHRSP, systolic BP (SBP), GFR, and proteinuria were measured before and after 4 weeks of treatment with vehicle (Veh), RLX (0.5 mg/kg per day s.c.), or RLX+PD123319 (AT2R antagonist; 3 mg/kg per day s.c.). Aortic endothelium-dependent relaxation and fibrosis of the kidney, heart, and aorta were assessed. Results: In 6MO SHRSP, RLX significantly enhanced GFR by approximately 25% (P=0.001) and reduced cardiac fibrosis (P=0.01) as compared with vehicle-treated counterparts. These effects were abolished or blunted by PD123319 coadministration. In 15MO females, RLX reduced interstitial renal (P=0.02) and aortic (P=0.003) fibrosis and lowered SBP (13±3 mm Hg; P=0.04) relative to controls. These effects were also blocked by PD123319 cotreatment (all P=0.05 versus RLX treatment alone). RLX also markedly improved vascular function by approximately 40% (P<0.001) in 15MO SHRSP, but this was not modulated by PD123319 cotreatment. Conclusions: The antifibrotic and organ-protective effects of RLX, when administered to a severe model of hypertension, conferred cardiorenal protection in adult and reproductively senescent female rats to a great extent via an AT2R-mediated mechanism.
Background: The antifibrotic effects of recombinant human relaxin (RLX) in the kidney are dependent on an interaction between its cognate receptor (RXFP1) and the angiotensin type 2 receptor (AT2R) in male models of disease. Whether RLX has therapeutic effects, which are also mediated via AT2R, in hypertensive adult and aged/reproductively senescent females is unknown. Thus, we determined whether treatment with RLX provides cardiorenal protection via an AT2R-dependent mechanism in adult and aged female stroke-prone spontaneously hypertensive rats (SHRSPs). Methods: In 6-month-old (6MO) and 15-month-old ([15MO]; reproductively senescent) female SHRSP, systolic BP (SBP), GFR, and proteinuria were measured before and after 4 weeks of treatment with vehicle (Veh), RLX (0.5 mg/kg per day s.c.), or RLX+PD123319 (AT2R antagonist; 3 mg/kg per day s.c.). Aortic endothelium-dependent relaxation and fibrosis of the kidney, heart, and aorta were assessed. Results: In 6MO SHRSP, RLX significantly enhanced GFR by approximately 25% (P=0.001) and reduced cardiac fibrosis (P=0.01) as compared with vehicle-treated counterparts. These effects were abolished or blunted by PD123319 coadministration. In 15MO females, RLX reduced interstitial renal (P=0.02) and aortic (P=0.003) fibrosis and lowered SBP (13±3 mm Hg; P=0.04) relative to controls. These effects were also blocked by PD123319 cotreatment (all P=0.05 versus RLX treatment alone). RLX also markedly improved vascular function by approximately 40% (P<0.001) in 15MO SHRSP, but this was not modulated by PD123319 cotreatment. Conclusions: The antifibrotic and organ-protective effects of RLX, when administered to a severe model of hypertension, conferred cardiorenal protection in adult and reproductively senescent female rats to a great extent via an AT2R-mediated mechanism.
Authors: Dan O Debrah; Jackie Novak; Julianna E Matthews; Rolando J Ramirez; Sanjeev G Shroff; Kirk P Conrad Journal: Endocrinology Date: 2006-07-27 Impact factor: 4.736
Authors: Bryna S M Chow; Martina Kocan; Matthew Shen; Yan Wang; Lei Han; Jacqueline Y Chew; Chao Wang; Sanja Bosnyak; Katrina M Mirabito-Colafella; Giannie Barsha; Belinda Wigg; Elizabeth K M Johnstone; Mohammed A Hossain; Kevin D G Pfleger; Kate M Denton; Robert E Widdop; Roger J Summers; Ross A D Bathgate; Tim D Hewitson; Chrishan S Samuel Journal: J Am Soc Nephrol Date: 2019-09-11 Impact factor: 10.121
Authors: Sandra L Garber; Yelena Mirochnik; Carolyn Brecklin; Leonid Slobodskoy; Jose A L Arruda; George Dunea Journal: Am J Nephrol Date: 2003 Jan-Feb Impact factor: 3.754
Authors: Chao Wang; Anita A Pinar; Robert E Widdop; Mohammed A Hossain; Ross A D Bathgate; Kate M Denton; Barbara K Kemp-Harper; Chrishan S Samuel Journal: FASEB J Date: 2020-04-16 Impact factor: 5.191
Authors: Bryna S Man Chow; Martina Kocan; Sanja Bosnyak; Mohsin Sarwar; Belinda Wigg; Emma S Jones; Robert E Widdop; Roger J Summers; Ross A D Bathgate; Tim D Hewitson; Chrishan S Samuel Journal: Kidney Int Date: 2014-01-15 Impact factor: 10.612
Authors: Katrina M Mirabito; Lucinda M Hilliard; Geoffrey A Head; Robert E Widdop; Kate M Denton Journal: Biol Sex Differ Date: 2014-09-16 Impact factor: 5.027
Authors: Felipe Tapia Cáceres; Tracey A Gaspari; Mohammed Akhter Hossain; Chrishan S Samuel Journal: Int J Mol Sci Date: 2022-06-25 Impact factor: 6.208